These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15813839)

  • 1. Controlled trial of interventions to increase testing and treatment for Helicobacter pylori and reduce medication use in patients with chronic acid-related symptoms.
    Majumdar SR; Ross-Degnan D; Farraye FA; Lee M; Kemp JA; Lecates RF; Henning JM; Tunis SR; Schrammel P; Soumerai SB
    Aliment Pharmacol Ther; 2005 Apr; 21(8):1029-39. PubMed ID: 15813839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease.
    Allison JE; Hurley LB; Hiatt RA; Levin TR; Ackerson LM; Lieu TA
    Arch Intern Med; 2003 May; 163(10):1165-71. PubMed ID: 12767952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
    Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T
    Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial.
    Jarbol DE; Kragstrup J; Stovring H; Havelund T; Schaffalitzky de Muckadell OB
    Am J Gastroenterol; 2006 Jun; 101(6):1200-8. PubMed ID: 16771937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
    Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic treatment and H. pylori eradication therapy for nonulcer dyspepsia.
    Smucny J
    Am Fam Physician; 2001 Nov; 64(9):1605-8. PubMed ID: 11730316
    [No Abstract]   [Full Text] [Related]  

  • 7. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for the management of dyspepsia.
    Talley NJ; Vakil N;
    Am J Gastroenterol; 2005 Oct; 100(10):2324-37. PubMed ID: 16181387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: Helicobacter pylori and gastro-oesophageal reflux disease.
    Delaney B; McColl K
    Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():32-40. PubMed ID: 16042657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
    Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
    Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-week versus two-week H2-receptor antagonist in combination with amoxicillin and tinidazole for eradication of Helicobacter pylori infection.
    Hsu CC; Chen JJ; Hu TH; Lu SN; Changchien CS
    Hepatogastroenterology; 2005; 52(65):1617-21. PubMed ID: 16201128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitors and Helicobacter pylori gastritis: friends or foes?
    Kuipers EJ
    Basic Clin Pharmacol Toxicol; 2006 Sep; 99(3):187-94. PubMed ID: 16930292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey of dyspepsia management in community.
    Luman W; Ng HS
    Singapore Med J; 2001 Jan; 42(1):26-9. PubMed ID: 11361234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders.
    Bursey F; Crowley M; Janes C; Turner CJ
    CMAJ; 2000 Mar; 162(6):817-23. PubMed ID: 10750472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors.
    Raghunath AS; Hungin AP; Mason J; Jackson W
    Aliment Pharmacol Ther; 2009 Feb; 29(4):431-9. PubMed ID: 19035981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of the rehaemorrhage of bleeding peptic ulcers: effects of Helicobacter pylori eradication and acid suppression.
    Kikkawa A; Iwakiri R; Ootani H; Ootani A; Fujise T; Sakata Y; Amemori S; Tsunada S; Sakata H; Koyama T; Fujimoto K
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():79-84. PubMed ID: 15943852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States.
    Ladabaum U; Fendrick AM; Glidden D; Scheiman JM
    Am J Gastroenterol; 2002 Dec; 97(12):3007-14. PubMed ID: 12492183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current indications for acid suppressants in dyspepsia.
    Bytzer P; Talley NJ
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):385-400. PubMed ID: 11403534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence and adherence to proton pump inhibitors in daily clinical practice.
    Van Soest EM; Siersema PD; Dieleman JP; Sturkenboom MC; Kuipers EJ
    Aliment Pharmacol Ther; 2006 Jul; 24(2):377-85. PubMed ID: 16842465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
    Güliter S; Keleş H; Ozkurt ZN; Cengiz DU; Kolukisa E
    Turk J Gastroenterol; 2005 Mar; 16(1):29-33. PubMed ID: 16252185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.